Work

664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.060

Authors: A.R. Kydd, M-J. Lee, S. Lee, S. Rastogi, N. Sato, L. Cordes, L. Ley, O. Sierra Ortiz, J.J. Wright, H. Streicher, S. Steinberg, B. Saraiya, S.K. Pal, P.N. Lara, A. Mortazavi, R. Costello, S. Niglio, D. Bottaro, J. Trepel, A.B. Apolo

Institutions: National Cancer Institute, Center for Cancer Research, National Institutes of Health, Rutgers Cancer Institute, City Of Hope National Medical Center, City of Hope, UC Davis Comprehensive Cancer Center, University of California, Davis, The Ohio State University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Gilead Sciences, Regeneron Pharmaceuticals, Exelixis, Incyte, Eisai, Astellas Pharma, Ipsen, Genentech, Pharmacyclics, Janssen Biotech

OpenAlex ID: W3203343929

FWCI:

Cites:

Cited by:

Related to: 10